Cancer Family
Hematopoietic and Lymphoid Cell Neoplasm
CI-CAN-00000023Explore in graph →
HematologicNon-malignant4,231 active trials98 approved drugs1,009 evidence items
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000023Explore in graph →
Clinical trials
18,680 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT05443854 | Impact of Aminoglycosides-based Antibiotics Combination and Protective Isolation on Outcomes in Critically-ill Neutropenic Patients With Sepsis: (Combination-Lock01) | unknown | Phase 3 | 340 | Assistance Publique - Hôpitaux de ParisOTHER | 0 | Jul 5, 2022 | clinicaltrials |
| NCT03564470 | Precision Diagnosis Directing HDACi and TKI Target Therapy for Adult Ph-like ALL | unknown | Phase 2 / Phase 3 | 120 | Nanfang Hospital, Southern Medical UniversityOTHER | 1 | Jul 1, 2022 |
| clinicaltrials |
| NCT05441761 | Mitoxantrone Hydrochloride Liposomes in Combination With GDP in Relapsed/Refractory PTCL | unknown | Phase 1 / Phase 2 | 60 | Peking Union Medical College HospitalOTHER | 1 | Jul 1, 2022 | clinicaltrials |
| NCT05439538 | Serum NGAL IN Patients With Multiple Myeloma | unknown | — | 60 | Assiut UniversityOTHER | 0 | Jun 30, 2022 | clinicaltrials |
| NCT05430945 | A Study of BCMA-targeted CAR-T Cells Therapy for Refractory/Relapsed Multiple Myeloma | unknown | Early Phase 1 | 100 | Zhejiang UniversityOTHER | 1 | Jun 24, 2022 | clinicaltrials |
| NCT05428670 | The Efficacy and Safety of ZR2 Versus R-CHOP-like Regimen for Elderly Patients With Newly Diagnosed Diffuse Large B Cell Lymphoma. | unknown | Phase 2 | 150 | First Affiliated Hospital of Wenzhou Medical UniversityOTHER | 1 | Jun 23, 2022 | clinicaltrials |
| NCT05429918 | Ibrutinib Combined With R-CHOP/R-DHAP in Newly Diagnosed Mantle Cell Lymphoma Patients Who Aged ≤65 Years | unknown | — | 60 | Peking University Third HospitalOTHER | 1 | Jun 23, 2022 | clinicaltrials |
| NCT05426824 | The Whole-course Management of Pegaspargase in ENKTL | unknown | N/A | 72 | The First Affiliated Hospital with Nanjing Medical UniversityOTHER | 1 | Jun 22, 2022 | clinicaltrials |
| NCT04632316 | A Trial to Evaluate the Safety and Efficacy of oNKord® in Subjects With Acute Myeloid Leukemia | unknown | Phase 1 / Phase 2 | 33 | Glycostem Therapeutics BVINDUSTRY | 5 | Jun 21, 2022 | clinicaltrials |
| NCT05425654 | RL-MPV Followed by BBC HCT Using Autologous Stem Cells and Maintenance Therapy With Nivolumab for Newly Diagnosed PCNSL | unknown | Phase 2 | 30 | National Research Center for Hematology, RussiaNETWORK | 1 | Jun 21, 2022 | clinicaltrials |
| NCT05414162 | Multiparametric Cardiac MRI in Patients Under CAR T-cell Therapy | unknown | — | 60 | University Hospital, BonnOTHER | 1 | Jun 15, 2022 | clinicaltrials |
| NCT05410041 | Anti-CD19 CAR-Engineered NK Cells in the Treatment of Relapsed/Refractory B-cell Malignancies | unknown | Phase 1 | 15 | Beijing Boren HospitalOTHER | 1 | Jun 8, 2022 | clinicaltrials |
| NCT05406154 | Ibrutinib Combined With Bendamustine and Rituximab in Newly Diagnosed Mantle Cell Lymphoma Patients Who Aged > 65 Years | unknown | — | 60 | Peking University Third HospitalOTHER | 1 | Jun 6, 2022 | clinicaltrials |
| NCT05404516 | Combination of Sorafenib With Standard Therapy in Newly Diagnosed Adult CBF AML | unknown | Phase 2 | 88 | Nanfang Hospital, Southern Medical UniversityOTHER | 1 | Jun 3, 2022 | clinicaltrials |
| NCT04831658 | A Prospective Clinical Study of BTK Inhibitor, PD-1 and Formustine in the First-line Treatment of Primary Central Nervous System Lymphoma | unknown | Phase 1 / Phase 2 | 40 | Mingzhi ZhangOTHER | 1 | Jun 2, 2022 | clinicaltrials |
| NCT05398614 | SENL101 Autologous T Cell Injection in Adults With Relapsed or Refractory CD7+ Hematolymphoid Malignancies | unknown | Phase 1 | 18 | Hebei Senlang Biotechnology Inc., Ltd.INDUSTRY | 1 | Jun 1, 2022 | clinicaltrials |
| NCT04928105 | Senl-T7 CAR-T Cells for Treatment of Relapsed or Refractory CD7+ Lymphoma | unknown | N/A | 100 | Hebei Senlang Biotechnology Inc., Ltd.INDUSTRY | 1 | May 31, 2022 | clinicaltrials |
| NCT05398224 | R-MTX-zanbrutinib in Secondary CNS Lymphoma | unknown | Phase 2 | 45 | Peking UniversityOTHER | 1 | May 31, 2022 | clinicaltrials |
| NCT05110950 | Endobronchial Ultrasound Needle Aspiration With and Without Suction | unknown | N/A | 306 | Università Politecnica delle MarcheOTHER | 1 | May 26, 2022 | clinicaltrials |
| NCT05385263 | Addition of Nivolumab to Anti-CD-19 CAR-T Cells in Patients With Stable/Progressive DLBCL at Lymphodepletion | unknown | Phase 2 | 20 | Tel-Aviv Sourasky Medical CenterOTHER_GOV | 1 | May 26, 2022 | clinicaltrials |
| NCT05390749 | Sequential Treatment With RO-MTX After Pomalidomide, Orelabrutinib, Rituximab (POR) in Newly-diagnosed PCNSL | unknown | Phase 2 | 50 | Peking Union Medical College HospitalOTHER | 1 | May 25, 2022 | clinicaltrials |
| NCT05387226 | Intravenous Injection of Oncolytic Virus Injection (RT-01) in Patients With Relapsed or Refractory T-cell Lymphoma | unknown | Phase 1 | 6 | The First Affiliated Hospital of Bengbu Medical UniversityOTHER | 0 | May 24, 2022 | clinicaltrials |
| NCT05381077 | Evaluation of Whole Body Examination by MRI Integrating the "Zero Time Eco" Sequence (ZTE, Pseudo-CT) for the Detection of Bone Lesions in Multiple Myeloma: Comparison With Pet / CT and Whole Body Scanner(MM-ZTE) | unknown | N/A | 30 | Cliniques universitaires Saint-Luc- Université Catholique de LouvainOTHER | 1 | May 19, 2022 | clinicaltrials |
| NCT05382390 | Dual Growth Factor (rhTPO + G-CSF) and Chemotherapy Combination Regimen in Acute Myeloid Leukemia: Study Protocol for a Randomized Controlled Trial | unknown | Phase 3 | 130 | Huihan WangOTHER | 1 | May 19, 2022 | clinicaltrials |
| NCT05383014 | FLT3-ITD Gene Mutation and CD135 Expression in Acute Myeloid Leukemia. | unknown | — | 82 | Assiut UniversityOTHER | 0 | May 19, 2022 | clinicaltrials |
| NCT04951323 | Impact of the Immune System on Response to Anti-Coronavirus Disease 19 (COVID-19) Vaccine in Allogeneic Stem Cell Recipients (Covid Vaccin Allo) | unknown | Phase 3 | 50 | University of LiegeOTHER | 1 | May 18, 2022 | clinicaltrials |
| NCT05379647 | Natural Killer (NK) Cell Therapy for B-Cell Malignancies | unknown | Phase 1 | 24 | Zhejiang UniversityOTHER | 1 | May 18, 2022 | clinicaltrials |
| NCT02589548 | Brazilian Prospective Hodgkin Lymphoma Registry | unknown | — | 1,400 | Universidade Federal do Rio de JaneiroOTHER | 1 | May 17, 2022 | clinicaltrials |
| NCT05374226 | A Phase 1 Study to Evaluate JS019 in Advanced Solid Tumors or Lymphomas | unknown | Phase 1 | 172 | Suzhou Kebo Ruijun Biotechnology Co., LtdINDUSTRY | 1 | May 16, 2022 | clinicaltrials |
| NCT04886206 | Injection of Lymphocytes From Haplo-identical Donor Following Chemotherapy in Patients With High-risk Acute Myeloblastic Leukemia Not Eligible for an Allogeneic Hematopoietic Stem Cell Transplantation(ILDA) | unknown | Phase 1 | 12 | Nantes University HospitalOTHER | 1 | May 11, 2022 | clinicaltrials |
| NCT02623010 | Bruton's Tyrosine Kinase Inhibitor Ibrutinib as Maintenance Treatment in Elderly Patients With Primary CNS Lymphoma | unknown | Phase 2 | 30 | Rabin Medical CenterOTHER | 1 | May 10, 2022 | clinicaltrials |
| NCT03958916 | Prospective Multicenters Clinical Cohort Study of Stratified Treatment of Chinese Children With BL/DLBCL | unknown | — | 500 | Sun Yat-sen UniversityOTHER | 1 | May 9, 2022 | clinicaltrials |
| NCT03971305 | A Prospective Multicenters Clinical Cohort Study of Stratified Treatment of Chinese Children With Systemic ALK(+) ALCL | unknown | — | 300 | Sun Yat-sen UniversityOTHER | 1 | May 9, 2022 | clinicaltrials |
| NCT03971318 | A Prospective Multicenters Clinical Cohort Study of Stratified Treatment of Chinese Children With LBL | unknown | — | 300 | Sun Yat-sen UniversityOTHER | 1 | May 9, 2022 | clinicaltrials |
| NCT04624984 | PD-1 Inhibitor or PD-1 Inhibitor Plus GVD for Relapsed/Refractory CHL | unknown | Phase 2 | 42 | Sun Yat-sen UniversityOTHER | 1 | May 9, 2022 | clinicaltrials |
| NCT05364177 | 68Ga-pentixather and 68Ga-pentixafor PET/CT in Multiple Myeloma | unknown | Early Phase 1 | 100 | Peking Union Medical College HospitalOTHER | 1 | May 6, 2022 | clinicaltrials |
| NCT05364359 | Individual Dietary Counseling Based on Taste-tests in Patients With Hematological Cancer in Cytostatic Therapy(HCP) | unknown | N/A | 40 | University of CopenhagenOTHER | 1 | May 6, 2022 | clinicaltrials |
| NCT05362942 | Combination of Venetoclax, Hypomethylation Agent and Low-dose Cytarabine as a Salvage Therapy for Acute Myeloid Leukemia | unknown | Phase 2 | 52 | Beijing 302 HospitalOTHER | 0 | May 5, 2022 | clinicaltrials |
| NCT04709458 | Safety and Early Efficacy Study of TBX-2400 in Patients With AML or Myelofibrosis | unknown | Phase 1 | 10 | Taiga Biotechnologies, Inc.INDUSTRY | 2 | May 3, 2022 | clinicaltrials |
| NCT05154474 | Assessment of Sarcopenia at Diagnosis for Patients With Previously Untreated Metastatic Cancer or Hematologic Malignancy(SPACE2) | unknown | — | 150 | WepromOTHER | 1 | May 3, 2022 | clinicaltrials |
| NCT03671850 | VT-EBV-N for Treatment of Severe in EBV Positive Extranodal NK/T Cell Lymphoma Patients | unknown | Phase 2 | 48 | ViGenCell Inc.INDUSTRY | 1 | Apr 29, 2022 | clinicaltrials |
| NCT05330364 | Study of Chidamide Combined With Cladribine in Refractory/Relapsed Acute Myeloid Leukemia | unknown | Phase 2 | 31 | Ge ZhengOTHER | 1 | Apr 29, 2022 | clinicaltrials |
| NCT05353205 | A Study of the Efficacy and Safety of Flumatinib in Patients With Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase. | unknown | Phase 4 | 200 | Jiangsu Hansoh Pharmaceutical Co., Ltd.INDUSTRY | 1 | Apr 29, 2022 | clinicaltrials |
| NCT04327583 | Impact of the Coordinated Intervention of the Healthcare Facilities Pharmacist and the Dispensary Pharmacist on the Care Pathway for Cancer Patients Treated With Oral Therapy(IPPACTTO) | unknown | N/A | 396 | Institut Cancerologie de l'OuestOTHER | 1 | Apr 28, 2022 | clinicaltrials |
| NCT04678089 | Evaluation of Clinical Treatment of Multiple Myeloma Based on Multi-omics | unknown | — | 350 | Beijing Chao Yang HospitalOTHER | 1 | Apr 28, 2022 | clinicaltrials |
| NCT05350852 | Evaluate the Safety, Efficacy and Pharmacokinetics of ThisCART19A in Patients With MRD+ B-ALL | unknown | Phase 1 | 16 | Zhejiang UniversityOTHER | 1 | Apr 28, 2022 | clinicaltrials |
| NCT05277493 | A Registry of Chinese AL Amyloidosis Patients Treated With Subcutaneous or Intravenous Daratumumab | unknown | — | 500 | Peking Union Medical College HospitalOTHER | 1 | Apr 27, 2022 | clinicaltrials |
| NCT05349266 | Assessment of Safety and Efficacy of ThisCART19A in Adult Patients With B-NHL After Failure of Autologous Chimeric Antigen Receptor T- Cell(CAR-T) Therapy | unknown | Phase 1 | 16 | Zhejiang UniversityOTHER | 1 | Apr 27, 2022 | clinicaltrials |
| NCT05053425 | Bcl-2 Inhibitors Combined With Azacytidine and Chemotherapy in Elderly Patients With Previously Untreated AML | unknown | N/A | 30 | LanZhou UniversityOTHER | 1 | Apr 26, 2022 | clinicaltrials |
Data updated 23 days agoSource updated Jul 5, 2022source: clinicaltrials